Drug Trial Radar · NCT04940741
Efficacy and Safety of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain
Last checked: Nov 19, 2026Latest source record: Apr 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
820
Actual
Start
Jul 7, 2021
Primary completion
Mar 26, 2024
Study completion Mar 26, 2024
Sponsor
- Lead sponsor
- Vertanical GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jun 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Analysis of the efficacy, maintenance of efficacy, long-term safety, and investigation of the potential for dependence and abuse and the effect of abrupt drug withdrawal of VER-01 in the treatment of patients with chronic non-specific low back pain when drug treatment is indicated and previous optimised treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.
Conditions
- Chronic Non-specific Low Back Pain
Interventions
VER-01Drug
standardised cannabis extract (containing 21 mg THC per gram drug product)
PlaceboOther
comparator without active ingredient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase A: Efficacy based on pain reductionTime frame: Baseline up to 15 weeks
- Phase B: Safety based on occurrence of treatment-related AEs/SAEsTime frame: Up to 29 weeks
- Phase C: Safety based on occurrence of treatment-related AEs/SAEsTime frame: Up to 28 weeks
- Phase D: Maintenance of efficacyTime frame: Up to 4 weeks (from date of randomization R2 until the first day of treatment failure)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Emovis GmbH
Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.